Produits et services

Pharmaceutical preparations.

Abrégé

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 9/08 - Solutions
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present invention relates to a method for selecting or adjusting a therapy regimen for a subject having been diagnosed with celiac disease, wherein the therapy regimen comprises at least the treatment of celiac disease by administering a therapeutically effective amount of at least one transglutaminase 2 (TG2) inhibitor to said subject, wherein selecting or adjusting the therapy regimen is based on human leukocyte antigen DQ haplotypes of said subject.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Produits et services

(1) Pharmaceutical preparations, namely in the fields of gastroenterology and hepatology.

Produits et services

Pharmaceutical preparations, namely in the fields of gastroenterology and hepatology

Produits et services

Medicinal preparations and substances; Pharmaceuticals and natural remedies; Pharmaceutical drugs; Pharmaceutical products and preparations; Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic agents for pharmaceutical use; Therapeutic companion diagnostics in the form of reagents for assisting with predicting the effects of medication, the existence or non-existence of side effects and with selecting medication to be administered relating to the respective patient; In vitro diagnostic preparations, in particular Reagents, solutions and test strips for analysing biological samples for clinical use and for medical and diagnostic purposes; Reagents, Solutions and Test strips For medical and clinical use; Diagnostic reagents for medical use, for analysing body fluids, in particular saliva and blood; Test strips for detecting substances in body fluids, in particular saliva and blood, for laboratory use and for medical use; Compounds, in particular Active substances and/or reagents, materials and preparations for clinical diagnostics or therapeutic companion diagnostics; Chemical preparations for use in medical diagnostics, in particular preparations for personalised medicine and/or gene analysis and/or genome sequencing; Chemical preparations for use in RNA, DNA and antibody analysis, in particular in the field of personalised medicine; Ready-to-use injections filled with pharmaceutical preparations; Dietary supplements and dietetic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of inflammatory and bacterial diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of bacterial disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of immune system disorders and autoimmune disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for immune system adjustment; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for regulating the immune system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of digestive system diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of hypertension; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for activating cell function; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the peripheral nervous system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of kidney diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of liver diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of metabolic disorders and diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of skin disorders and problems; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of bone diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of rheumatic diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of depression; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of musculoskeletal diseases; Pharmaceuticals and Pharmaceutical preparations, The aforesaid goods for the prevention and treatment of gastrointestinal diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in organ transplantation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in dermatology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in urology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hypercholesterolemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hyperlipidemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of osteoporosis; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of the digestive tract, including the oesophagus; Pharmaceutical preparations and Pharmaceuticals, namely Capsules, Powders, Tablets, Sachets, Juices, Suspensions, Granules, enema preparations, Suppositories and Suppositories [for rectal application], rectal foam for pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, in particular including plant-based preparations, and preparations for the treatment of constipation, coeliac disease, haemorrhoids, pancreatitis [in particular acute pancreatitis], high cholesterol, zinc deficiency, irritable bowel syndrome or supportive therapies for diarrhoea; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for intestinal cleansing before a colonoscopy; Immunosuppressants and cortisol preparations for the treatment of organ transplants, inflammatory bowel disease, skin diseases and rheumatic joint inflammation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for supporting the body in connection with an organ transplant; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of rheumatoid arthritis, chronic inflammatory bowel disease, in particular Crohn's disease or ulcerative colitis, systemic lupus erythematosus, dermatomyositis, polymyositis, chronic active autoimmune hepatitis, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of chronic intestinal inflammation, in particular microscopic colitis, chronic inflammation of the liver [autoimmune hepatitis] and inflammatory diseases of the oesophagus [eosinophilic oesophagitis]; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the dissolving of gallstones, for the treatment of chronic diseases of the biliary tract and for the treatment of liver diseases, in particular cirrhosis of the liver or liver disease in connection with cystic fibrosis [mucoviscidosis]. Medical apparatus and instruments; Pharmaceutical instruments; Medicinal products, in particular Medical devices for conducting in-vitro diagnostic test procedures; Injection device for pharmaceuticals; Applicators for pharmaceutical preparations; Apparatus for the administration of medicines and pharmaceutical preparations; Pre-filled syringes for medical purposes; Autoinjectors for the administration of pharmaceutical preparations; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body; Implantable subcutaneous drug delivery devices; Medical instruments for therapeutic drug monitoring; Metering pumps for delivering drugs in measured quantities [medical use]; Applicators for medications; Receptacles for applying medicines; Diagnostic apparatus for medical purposes; Medical apparatus and instruments for extracting body fluids, in particular saliva and blood samples; Medical diagnostic apparatus and instruments for analysing body fluids, in particular saliva and blood; Medical apparatus and instruments, and components and fittings therefor, for analysing DNA, RNA and antibodies; Clinical and medical laboratory test apparatus for diagnostic use in the following fields: Disease diagnostics, in particular Personalised medicine and companion diagnostics. Printed matter; Educational and teaching materials; Printed books, magazines, newspapers, and other paper-based media; All the aforesaid goods solely for use in the field of medical training and further training, in particular in the field of pharmacological training and further training. Advertising, marketing and promotional services; Public relations services; Promotion, advertising and marketing of on-line websites; Online advertisements; Computerised business promotion; Provision of space on web-sites for advertising goods and services; Dissemination of advertising for others via an on-line communications network on the internet; Human resources management and recruitment services; Business assistance, management and administrative services; Business consultancy and advisory services; Services in the the following fields: Organisational development, personnel development services, self improvement, Corporate communications services, Corporate branding; Advertising services to create corporate and brand identity; Distribution of advertising, marketing and promotional material; Product demonstrations and product display services; Services with regard to product presentation to the public; Provision and rental of advertising space, time and media; Trade show and commercial exhibition services; Conducting, arranging and organizing trade shows and trade fairs for commercial and advertising purposes; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Education and instruction services; Providing facilities for educational purposes; Entertainment, education and instruction services; Educational services in the healthcare sector; Organisation of conferences, exhibitions and competitions; Arranging and conducting of training courses, Arranging and conducting of meetings in the field of education; Arranging, conducting and organisation of training courses, arranging, organising and conducting meetings, Arranging, organising and conducting lectures, Arranging, organising and conducting of seminars, arranging, conducting and organizing webinars, Arranging, organisation and conducting of congresses and Arranging, conducting and organisation of symposiums, The aforesaid services in particular in the field of organisational development, personnel development, personality development, corporate communications, corporate branding; Publishing, reporting, and writing of texts; Publishing services (including electronic publishing services); Publishing services; Electronic publishing services; Publishing services; Providing electronic publications; Providing online electronic publications, not downloadable; Providing online videos, not downloadable; Providing on-line non-downloadable audio content; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Audio, video and multimedia productions; Multimedia publishing of printed matter; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Medical and pharmacological research services; Development of pharmaceutical preparations and medicines; Conducting clinical trials for pharmaceutical products; Consultancy relating to pharmaceutical research and development; Research and development for the pharmaceutical industry; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical drug development services; Inspection of pharmaceuticals; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Laboratory research services relating to pharmaceuticals; Medical analysis, in particular Test procedures in the following fields: Personalised medicine and companion diagnostics; Conducting of RNA, DNA and antibody analysis, in particular in the following fields: Personalised medicine and companion diagnostics; Development and research in the medical fields of gastroenterology and hepatology. Medical services, in particular Treatment methods in the following fields: Personalised medicine and companion diagnostics; Diagnostic services, in particular Companion diagnostics for assessing the effectiveness and/or safety of medicines; Medical and diagnostic services in the medical fields of gastroenterology and hepatology.

Produits et services

Medicinal preparations and substances; Pharmaceuticals and natural remedies; Pharmaceutical drugs; Pharmaceutical products and preparations; Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic agents for pharmaceutical use; Therapeutic companion diagnostics in the form of reagents for assisting with predicting the effects of medication, the existence or non-existence of side effects and with selecting medication to be administered relating to the respective patient; In vitro diagnostic preparations, in particular Reagents, solutions and test strips for analysing biological samples for clinical use and for medical and diagnostic purposes; Reagents, Solutions and Test strips For medical and clinical use; Diagnostic reagents for medical use, for analysing body fluids, in particular saliva and blood; Test strips for detecting substances in body fluids, in particular saliva and blood, for laboratory use and for medical use; Compounds, in particular Active substances and/or reagents, materials and preparations for clinical diagnostics or therapeutic companion diagnostics; Chemical preparations for use in medical diagnostics, in particular preparations for personalised medicine and/or gene analysis and/or genome sequencing; Chemical preparations for use in RNA, DNA and antibody analysis, in particular in the field of personalised medicine; Ready-to-use injections filled with pharmaceutical preparations; Dietary supplements and dietetic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of inflammatory and bacterial diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of bacterial disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of immune system disorders and autoimmune disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for immune system adjustment; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for regulating the immune system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of digestive system diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of hypertension; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for activating cell function; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the peripheral nervous system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of kidney diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of liver diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of metabolic disorders and diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of skin disorders and problems; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of bone diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of rheumatic diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of depression; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of musculoskeletal diseases; Pharmaceuticals and Pharmaceutical preparations, The aforesaid goods for the prevention and treatment of gastrointestinal diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in organ transplantation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in dermatology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in urology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hypercholesterolemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hyperlipidemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of osteoporosis; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of the digestive tract, including the oesophagus; Pharmaceutical preparations and Pharmaceuticals, namely Capsules, Powders, Tablets, Sachets, Juices, Suspensions, Granules, enema preparations, Suppositories and Suppositories [for rectal application], rectal foam for pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, in particular including plant-based preparations, and preparations for the treatment of constipation, coeliac disease, haemorrhoids, pancreatitis [in particular acute pancreatitis], high cholesterol, zinc deficiency, irritable bowel syndrome or supportive therapies for diarrhoea; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for intestinal cleansing before a colonoscopy; Immunosuppressants and cortisol preparations for the treatment of organ transplants, inflammatory bowel disease, skin diseases and rheumatic joint inflammation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for supporting the body in connection with an organ transplant; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of rheumatoid arthritis, chronic inflammatory bowel disease, in particular Crohn's disease or ulcerative colitis, systemic lupus erythematosus, dermatomyositis, polymyositis, chronic active autoimmune hepatitis, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of chronic intestinal inflammation, in particular microscopic colitis, chronic inflammation of the liver [autoimmune hepatitis] and inflammatory diseases of the oesophagus [eosinophilic oesophagitis]; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the dissolving of gallstones, for the treatment of chronic diseases of the biliary tract and for the treatment of liver diseases, in particular cirrhosis of the liver or liver disease in connection with cystic fibrosis [mucoviscidosis]. Medical apparatus and instruments; Pharmaceutical instruments; Medicinal products, in particular Medical devices for conducting in-vitro diagnostic test procedures; Injection device for pharmaceuticals; Applicators for pharmaceutical preparations; Apparatus for the administration of medicines and pharmaceutical preparations; Pre-filled syringes for medical purposes; Autoinjectors for the administration of pharmaceutical preparations; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body; Implantable subcutaneous drug delivery devices; Medical instruments for therapeutic drug monitoring; Metering pumps for delivering drugs in measured quantities [medical use]; Applicators for medications; Receptacles for applying medicines; Diagnostic apparatus for medical purposes; Medical apparatus and instruments for extracting body fluids, in particular saliva and blood samples; Medical diagnostic apparatus and instruments for analysing body fluids, in particular saliva and blood; Medical apparatus and instruments, and components and fittings therefor, for analysing DNA, RNA and antibodies; Clinical and medical laboratory test apparatus for diagnostic use in the following fields: Disease diagnostics, in particular Personalised medicine and companion diagnostics. Printed matter; Educational and teaching materials; Printed books, magazines, newspapers, and other paper-based media; All the aforesaid goods solely for use in the field of medical training and further training, in particular in the field of pharmacological training and further training. Advertising, marketing and promotional services; Public relations services; Promotion, advertising and marketing of on-line websites; Online advertisements; Computerised business promotion; Provision of space on web-sites for advertising goods and services; Dissemination of advertising for others via an on-line communications network on the internet; Human resources management and recruitment services; Business assistance, management and administrative services; Business consultancy and advisory services; Services in the the following fields: Organisational development, personnel development services, self improvement, Corporate communications services, Corporate branding; Advertising services to create corporate and brand identity; Distribution of advertising, marketing and promotional material; Product demonstrations and product display services; Services with regard to product presentation to the public; Provision and rental of advertising space, time and media; Trade show and commercial exhibition services; Conducting, arranging and organizing trade shows and trade fairs for commercial and advertising purposes; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Education and instruction services; Providing facilities for educational purposes; Entertainment, education and instruction services; Educational services in the healthcare sector; Organisation of conferences, exhibitions and competitions; Arranging and conducting of training courses, Arranging and conducting of meetings in the field of education; Arranging, conducting and organisation of training courses, arranging, organising and conducting meetings, Arranging, organising and conducting lectures, Arranging, organising and conducting of seminars, arranging, conducting and organizing webinars, Arranging, organisation and conducting of congresses and Arranging, conducting and organisation of symposiums, The aforesaid services in particular in the field of organisational development, personnel development, personality development, corporate communications, corporate branding; Publishing, reporting, and writing of texts; Publishing services (including electronic publishing services); Publishing services; Electronic publishing services; Publishing services; Providing electronic publications; Providing online electronic publications, not downloadable; Providing online videos, not downloadable; Providing on-line non-downloadable audio content; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Audio, video and multimedia productions; Multimedia publishing of printed matter; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Medical and pharmacological research services; Development of pharmaceutical preparations and medicines; Conducting clinical trials for pharmaceutical products; Consultancy relating to pharmaceutical research and development; Research and development for the pharmaceutical industry; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical drug development services; Inspection of pharmaceuticals; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Laboratory research services relating to pharmaceuticals; Medical analysis, in particular Test procedures in the following fields: Personalised medicine and companion diagnostics; Conducting of RNA, DNA and antibody analysis, in particular in the following fields: Personalised medicine and companion diagnostics; Development and research in the medical fields of gastroenterology and hepatology. Medical services, in particular Treatment methods in the following fields: Personalised medicine and companion diagnostics; Diagnostic services, in particular Companion diagnostics for assessing the effectiveness and/or safety of medicines; Medical and diagnostic services in the medical fields of gastroenterology and hepatology.

Abrégé

Disclosed is an orally applicable suspension comprising a) topically acting micronized budesonide, b) an aqueous base, c) at least one viscosity-increasing agent selected from a methylcellulose or a derivative thereof, d) a buffering agent which allows the adjustment of the final suspension to a pH value of 3.5 to 4.5, e) an antimicrobial preservative, f) a suspension stabilizing agent, in particular ethylenediaminetetramethyl acetic acid, whereby the suspension has a dynamic viscosity in the range of 800 mPa*s to 2000 mPa*s and the final suspension contains a concentration of 0.1 mg/ml to 0.5 mg/ml budesonide for use in the treatment of eosinophilic esophagitis of a patient having an age of about 1 year to about 17 years whereby 0.5 to 1.0 mg budesonide are administered in 2.5 to 5.0 ml suspension once or twice a day.

Classes IPC  ?

• A61K 9/10 - DispersionsÉmulsions
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 47/38 - CelluloseSes dérivés
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Produits et services

Medicinal preparations and substances; Pharmaceuticals and natural remedies; Pharmaceutical drugs; Pharmaceutical products and preparations; Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic agents for pharmaceutical use; Dietary supplements and dietetic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of inflammatory and bacterial diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of bacterial disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of immune system disorders and autoimmune disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for immune system adjustment; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for regulating the immune system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of digestive system diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of hypertension; pharmaceutical preparations and agents for activating cellular function; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the peripheral nervous system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of kidney diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of liver diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of metabolic disorders and diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of skin disorders and problems; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of bone diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of rheumatic diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of depression; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of musculoskeletal diseases; Pharmaceutical products, products for preventing and treating stomach and intestinal disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in organ transplantation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in dermatology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in urology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hypercholesterolemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hyperlipidemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of osteoporosis; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of the digestive tract, including the oesophagus; Pharmaceutical preparations and Pharmaceuticals, namely Capsules, Powders, Tablets, Sachets, Juices, Suspensions, Granules, enema preparations, Suppositories and Suppositories [for rectal application], rectal foam for pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, in particular including plant-based preparations, and preparations for the treatment of constipation, coeliac disease, haemorrhoids, pancreatitis [in particular acute pancreatitis], high cholesterol, zinc deficiency, irritable bowel syndrome or supportive therapies for diarrhoea; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for intestinal cleansing before a colonoscopy; Immunosuppressants and cortisol preparations for the treatment of organ transplants, inflammatory bowel disease, skin diseases and rheumatic joint inflammation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for supporting the body in connection with an organ transplant; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of rheumatoid arthritis, chronic inflammatory bowel disease, in particular Crohn's disease or ulcerative colitis, systemic lupus erythematosus, dermatomyositis, polymyositis, chronic active autoimmune hepatitis, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of chronic intestinal inflammation, in particular microscopic colitis, chronic inflammation of the liver [autoimmune hepatitis] and inflammatory diseases of the oesophagus [eosinophilic oesophagitis]; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the dissolving of gallstones, for the treatment of chronic diseases of the biliary tract and for the treatment of liver diseases, in particular cirrhosis of the liver or liver disease in connection with cystic fibrosis [mucoviscidosis]. Medical apparatus and instruments; Pharmaceutical instruments; Injection device for pharmaceuticals; Applicators for pharmaceutical preparations; Apparatus for the administration of medicines and pharmaceutical preparations; Autoinjectors for the administration of pharmaceutical preparations; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body; Implantable subcutaneous drug delivery devices; Medical instruments for therapeutic drug monitoring; Metering pumps for delivering drugs in measured quantities [medical use]; Applicators for medications; Receptacles for applying medicines. Printed matter; Educational and teaching materials; Printed books, magazines, newspapers, and other paper-based media; All the aforesaid goods solely for use in the field of medical training and further training, in particular in the field of pharmacological training and further training. Advertising, marketing and promotional services; Public relations services; Promotion, advertising and marketing of on-line websites; Online advertisements; Computerised business promotion; Provision of space on web-sites for advertising goods and services; Dissemination of advertising for others via an on-line communications network on the internet; Human resources management and recruitment services; Business assistance, management and administrative services; Business consultancy and advisory services; Charitable activities: Organisational development, personnel development services and Personal development from an professional business perspective, Corporate communications services, Corporate branding; Advertising services to create corporate and brand identity; Distribution of advertising, marketing and promotional material; Product demonstrations and product display services; Services with regard to product presentation to the public; Provision and rental of advertising space, time and media; Trade show and commercial exhibition services; Conducting, arranging and organizing trade shows and trade fairs for commercial and advertising purposes; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Education and instruction services; Providing facilities for educational purposes; Entertainment, education and instruction services; Educational services in the healthcare sector; Organisation of conferences, exhibitions and competitions; Arranging and conducting of training courses, Arranging and conducting of meetings in the field of education; Arranging, conducting and organisation of training courses, arranging, organising and conducting meetings, Arranging, organising and conducting lectures, Arranging, organising and conducting of seminars, arranging, conducting and organizing webinars, Arranging, organisation and conducting of congresses and Arranging, conducting and organisation of symposiums, The aforesaid services in particular in the field of organisational development, personnel development, personality development, corporate communications, corporate branding; Publishing, reporting, and writing of texts; Publishing services (including electronic publishing services); Publishing services; Electronic publishing services; Publishing services; Providing electronic publications; Providing online electronic publications, not downloadable; Providing online videos, not downloadable; Providing on-line non-downloadable audio content; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Audio, video and multimedia productions; Multimedia publishing of printed matter; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Medical and pharmacological research services; Development of pharmaceutical preparations and medicines; Conducting clinical trials for pharmaceutical products; Consultancy relating to pharmaceutical research and development; Research and development for the pharmaceutical industry; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical drug development services; Inspection of pharmaceuticals; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Laboratory research services relating to pharmaceuticals.

Abrégé

The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic Crohn's disease.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 9/50 - Microcapsules
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole

Abrégé

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Orodispersible effervescent tablets comprising budesonide are administered to patients suffering from eosinophilic esophagitis whereby a complete mucosal healing (i.e., deep endoscopic AND deep histological remission) and even a deep disease remission (i.e., deep clinical AND deep endoscopic AND deep histological remission) is achieved by a treatment regimen of administering said orodispersible effervescent tablets for at least six weeks to twelve weeks for the induction period and thereafter up to three a years as maintenance treatment.

Classes IPC  ?

• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Produits et services

Pharmaceutical preparations for the treatment of the intestinal tract including the esophagus

Produits et services

Pharmaceutical preparations for the treatment of the intestinal tract and the liver

Abrégé

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Classes IPC  ?

• A01N 37/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques
• A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
• A01N 37/12 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe , dans lequel Cn représente un squelette carboné ne comportant pas de cycleLeurs thio-analogues
• A01N 37/44 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'azote lié au même squelette carboné par une liaison simple ou double, cet atome d'azote ne faisant pas partie d'un dérivé ou d'un thio-analogue d'un groupe carboxylique, p. ex. acides aminocarboxyliques
• A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/24 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations for the treatment of metabolic diseases and diseases of the digestive tract and liver.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Abrégé

The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) and/or non-alcoholic steatohepatitis, and its use in the prophylaxis and/or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H- imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2- dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and/or in the prophylaxis or treatment of a liver disease or liver disorder.

Classes IPC  ?

• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.

Classes IPC  ?

• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 9/20 - Pilules, pastilles ou comprimés

Abrégé

The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2- (2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl- 1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic Crohn's disease.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 9/50 - Microcapsules
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic Crohn's disease.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 9/50 - Microcapsules
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The invention describes the provision of an amorphous solid dispersion of RhuDex® choline salt. The oral, gastro-resistant formulation is provided with a specific release characteristic. Release is realized at pH values from 6 to 7 in the region of the upper intestine. This region is specifically advantageous if pharmaceutical formulations aim to reach the liver as the primary target organ.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/50 - Microcapsules
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Orodispersible effervescent tablets comprising budesonide are administered to patients suffering from eosinophilic esophagitis whereby a complete mucosal healing (i.e., deep endoscopic AND deep histological remission) and even a deep disease remission (i.e., deep clinical AND deep endoscopic AND deep histological remission) is achieved by a treatment regimen of administering said orodispersible effervescent tablets for at least six weeks to twelve weeks for the induction period and thereafter up to three years as maintenance treatment.

Classes IPC  ?

• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Abrégé

A compound of formula (I) or a salt thereof are provided: 3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 263/58 - BenzoxazolesBenzoxazoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement en position 2
• C07C 211/13 - Amines contenant au moins trois groupes amino liés au squelette carboné
• C07C 211/27 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons ayant des groupes amino reliés au cycle aromatique à six chaînons par l'intermédiaire de chaînes carbonées saturées
• C07C 215/10 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique avec un groupe amino et au moins deux groupes hydroxy liés au squelette carboné
• C07C 223/02 - Composés contenant des groupes amino et —CHO liés au même squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques du squelette carboné
• C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
• C07C 279/14 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
• C07C 309/30 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné de cycles aromatiques à six chaînons non condensés de cycles aromatiques à six chaînons substitués par des groupes alkyle
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse; the enema for rectal application described above, in which a dose of budesonide is 2.0 mg per dose; the enema for rectal application according to any one of the above, which is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; the enema for rectal application according to any one of the above, which has a foamy shape or a liquid shape.

Classes IPC  ?

• A61K 9/12 - AérosolsMousses
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) and/or non-alcoholic steatohepatitis, and its use in the prophylaxis and/or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2- ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H- imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2- dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2- enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and/or in the prophylaxis or treatment of a liver disease or liver disorder.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61K 9/20 - Pilules, pastilles ou comprimés

Abrégé

The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Produits et services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases

Produits et services

(1) Pharmaceutical preparations, namely for the domains of gastroenterology and hepatology.

Produits et services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders, pharmaceutical preparations for the treatment of hepatological diseases and disorders.

Abrégé

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 9/50 - Microcapsules
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases.

Produits et services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases.

Produits et services

Pharmaceuticals.

Produits et services

Pharmaceuticals.

Produits et services

Pharmaceuticals.

Abrégé

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application contains budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 12 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application comprises several doses whereby the most preferable dose of budesonide is 2.0 mg per dose. The enema for rectal application is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; has a foamy, more rigid to a more liquid, gel-like structure.

Classes IPC  ?

• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
• A61K 9/12 - AérosolsMousses
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Classes IPC  ?

• A01N 37/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A01N 37/12 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe , dans lequel Cn représente un squelette carboné ne comportant pas de cycleLeurs thio-analogues
• A01N 37/44 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'azote lié au même squelette carboné par une liaison simple ou double, cet atome d'azote ne faisant pas partie d'un dérivé ou d'un thio-analogue d'un groupe carboxylique, p. ex. acides aminocarboxyliques
• A61K 31/24 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro
• A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/20 - Pilules, pastilles ou comprimés

Abrégé

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmacokinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has very good medicinal safety.

Classes IPC  ?

• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/50 - Microcapsules
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/20 - Pilules, pastilles ou comprimés

Abrégé

A compound of formula (I) or a salt thereof are provided: 3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 263/58 - BenzoxazolesBenzoxazoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement en position 2
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07C 309/30 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné de cycles aromatiques à six chaînons non condensés de cycles aromatiques à six chaînons substitués par des groupes alkyle
• C07C 279/14 - Dérivés de la guanidine, c.-à-d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes guanidine liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
• C07C 211/13 - Amines contenant au moins trois groupes amino liés au squelette carboné
• C07C 215/10 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique avec un groupe amino et au moins deux groupes hydroxy liés au squelette carboné
• C07C 223/02 - Composés contenant des groupes amino et —CHO liés au même squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques du squelette carboné
• C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
• C07C 211/27 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons ayant des groupes amino reliés au cycle aromatique à six chaînons par l'intermédiaire de chaînes carbonées saturées

Produits et services

Pharmaceutical preparations and substances; Pharmaceutical drugs; Nutritional supplements. Medical and pharmacological research services; Drug discovery services; Provision of research services; Scientific research for medical purposes; Pharmaceutical research services; Inspection of pharmaceuticals; Pharmaceutical research and development; Pharmaceutical drug development services; Pharmaceutical products development; Laboratory research services relating to pharmaceuticals; Consultancy pertaining to pharmacology; Consultancy in the field of pharmaceutical research; Development of pharmaceutical preparations and medicines; Research on the subject of pharmaceuticals; Consultancy relating to pharmaceutical research and development; Scientific research in the field of pharmacy; Services for assessing the efficiency of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Information technology services for the pharmaceutical and healthcare industries. Pharmacy advice; Pharmaceutical services; Pharmaceutical advice.

Abrégé

The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Produits et services

Pharmaceutical preparations.

Produits et services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases.

Produits et services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases

Abrégé

The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino

Abrégé

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Classes IPC  ?

• A01N 37/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A01N 37/12 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe , dans lequel Cn représente un squelette carboné ne comportant pas de cycleLeurs thio-analogues
• A01N 37/44 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'azote lié au même squelette carboné par une liaison simple ou double, cet atome d'azote ne faisant pas partie d'un dérivé ou d'un thio-analogue d'un groupe carboxylique, p. ex. acides aminocarboxyliques
• A61K 31/24 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro
• A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine

Abrégé

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application contains budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 12 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application comprises several doses whereby the most preferable dose of budesonide is 2.0 mg per dose. The enema for rectal application is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse: has a foamy, more rigid to a more liquid, gel-like structure.

Classes IPC  ?

• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61K 9/08 - Solutions
• A61K 9/12 - AérosolsMousses
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Abrégé

Compounds of formula (I) and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

Compound of formula (I) and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Produits et services

(1) Intestinal disorder medicine for the treatment of ulcerative colitis.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations for the treatment of inflammation of the upper gastrointestinal tract

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Abrégé

The invention relates to an oral gastric-juice resistant high dose tablet comprising mesalazine as an active substance. The invention also relates to the use thereof.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Abrégé

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
• C07J 7/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de deux atomes de carbone

Abrégé

The invention relates to a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically-compatible salt or derivative thereof, and at least 80 wt.% of a solid fat or a mixture of different solid fats in relation to the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Classes IPC  ?

• A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine

Abrégé

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine

Produits et services

Medicine; chemical preparations for pharmaceutical purposes; nutritional supplements; pharmaceutical preparations. Scientific services and research relating thereto; services in the fields of science and technology.

Produits et services

Medicine; Chemical preparations for pharmaceutical purposes; Nutritional supplements; Pharmaceutical preparations. Scientific services and research relating thereto; Science and technology services.

Produits et services

Pharmaceutical preparations, other than for prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Produits et services

Pharmaceutical preparations, namely for treating the digestive tract.